OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients

Four of 21 renal transplant recipients treated with OKT3 for rejection episodes developed a second sustained (approximately 2 weeks) depression in CD3 peripheral blood lymphocyte cell-surface-marker expression. This occurred after OKT3 therapy had ceased, subsequent to a return toward baseline CD3 l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation 1990-02, Vol.49 (2), p.408-415
Hauptverfasser: CARRENO, M, WEN-CHIC YANG, ESQUENAZI, V, FULLER, L, BURKE, G, MILGROM, M, ROTH, D, DINESH RANJAN, MILLER, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 415
container_issue 2
container_start_page 408
container_title Transplantation
container_volume 49
creator CARRENO, M
WEN-CHIC YANG
ESQUENAZI, V
FULLER, L
BURKE, G
MILGROM, M
ROTH, D
DINESH RANJAN
MILLER, J
description Four of 21 renal transplant recipients treated with OKT3 for rejection episodes developed a second sustained (approximately 2 weeks) depression in CD3 peripheral blood lymphocyte cell-surface-marker expression. This occurred after OKT3 therapy had ceased, subsequent to a return toward baseline CD3 levels seen before OKT3 therapy was instituted. The second decrease in CD3 T cell counts was dissociated from CD2 marker T cell counts using flow cytometry and coincided with transient cytomegaloviral infections. Three phases of immunosuppression were defined in these 4 patients: phase I (during OKT3 treatment); phase II (after treatment when CD3 counts were reconstituted); and phase III (when CD3 counts again were depressed). During phase III, serum of the 4 affected patients could transfer a blocking effect on the expression of the CD3 marker of peripheral blood T cells of "normal" laboratory volunteers. Contained in these sera were human IgG antibodies that bound on Western blot analysis and by radioautography after immunoprecipitation to a protein band of a T cell membrane lysate with an m.w. of 23 kD. The reaction was identical to that seen with OKT3 (immunoprecipitation). Moreover, this Western blot binding could be virtually (but not completely) eliminated by multiple absorptions of the T cell membrane lysate with OKT3. By using an affinity-purified human anti-OKT3 IgG from one of the 4 patients, it was possible to immunoabsorb from phase III sera the CD3 blocking activity as well as the binding to the 23 KD protein band. A reverse immune absorption by the phase III sera with the anti-OKT3 IgG after ultracentrifugation prevented the anti-OKT3 IgG from binding to OKT3 coated plates in solid-phase radioimmunoassay. These data support the notion that autoimmune human anti-anti-id (Ab2) antibodies can occasionally be generated by treatment with OKT3, which are directed against CD3 complex epitopes similar to the ligand of OKT3.
doi_str_mv 10.1097/00007890-199002000-00036
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79648454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15573913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-5cdcfba8e4e9f9b826f96e9af96bf691036334345de03b5458e17322647e34333</originalsourceid><addsrcrecordid>eNqFUdFOHSEQJU2N3qqfYMJD07dtYYEFHhtTtamJL_q8YdlZg-7Cyuza3H692Hu1jyUZyJw5c4A5hFDOvnJm9TdWljaWVdxaxuqSVSVE84FsuBKyaphhH8mGMckrLoQ-Ip8QHwpFCa0PySFvjFXcbsifm1-3gobYr34JKdLn4GjoQ1q2c_A0wvI75UekaaBTyDnlKkzuHmiYpjUmXOc5A2J4BuriEnbo_Zi6dQwRiyzNEN1Il-wizmPhFMCHOUBc8IQcDG5EON2fx-Tu4sft-VV1fXP58_z7deVlzZZK-d4PnTMgwQ62M3Uz2AasK3s3NJaXXwshhVQ9MNEpqQxwLeq6kRoKLsQx-bLTnXN6WgGXdgroYSzPgbRiq20jjVTyv0SulBaWvyqaHdHnhJhhaOdc5pK3LWftqz_tmz_tuz_tX39K69n-jrWboP_XuDOk1D_v6w69G4cyOB_wnaa4rg0T4gU5oZqH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15573913</pqid></control><display><type>article</type><title>OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>CARRENO, M ; WEN-CHIC YANG ; ESQUENAZI, V ; FULLER, L ; BURKE, G ; MILGROM, M ; ROTH, D ; DINESH RANJAN ; MILLER, J</creator><creatorcontrib>CARRENO, M ; WEN-CHIC YANG ; ESQUENAZI, V ; FULLER, L ; BURKE, G ; MILGROM, M ; ROTH, D ; DINESH RANJAN ; MILLER, J</creatorcontrib><description>Four of 21 renal transplant recipients treated with OKT3 for rejection episodes developed a second sustained (approximately 2 weeks) depression in CD3 peripheral blood lymphocyte cell-surface-marker expression. This occurred after OKT3 therapy had ceased, subsequent to a return toward baseline CD3 levels seen before OKT3 therapy was instituted. The second decrease in CD3 T cell counts was dissociated from CD2 marker T cell counts using flow cytometry and coincided with transient cytomegaloviral infections. Three phases of immunosuppression were defined in these 4 patients: phase I (during OKT3 treatment); phase II (after treatment when CD3 counts were reconstituted); and phase III (when CD3 counts again were depressed). During phase III, serum of the 4 affected patients could transfer a blocking effect on the expression of the CD3 marker of peripheral blood T cells of "normal" laboratory volunteers. Contained in these sera were human IgG antibodies that bound on Western blot analysis and by radioautography after immunoprecipitation to a protein band of a T cell membrane lysate with an m.w. of 23 kD. The reaction was identical to that seen with OKT3 (immunoprecipitation). Moreover, this Western blot binding could be virtually (but not completely) eliminated by multiple absorptions of the T cell membrane lysate with OKT3. By using an affinity-purified human anti-OKT3 IgG from one of the 4 patients, it was possible to immunoabsorb from phase III sera the CD3 blocking activity as well as the binding to the 23 KD protein band. A reverse immune absorption by the phase III sera with the anti-OKT3 IgG after ultracentrifugation prevented the anti-OKT3 IgG from binding to OKT3 coated plates in solid-phase radioimmunoassay. These data support the notion that autoimmune human anti-anti-id (Ab2) antibodies can occasionally be generated by treatment with OKT3, which are directed against CD3 complex epitopes similar to the ligand of OKT3.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-199002000-00036</identifier><identifier>PMID: 1689519</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adolescent ; Antibodies, Anti-Idiotypic - immunology ; Antibodies, Anti-Idiotypic - isolation &amp; purification ; Antibodies, Monoclonal - immunology ; Antigens, CD - analysis ; Antigens, Differentiation, T-Lymphocyte - analysis ; Antigens, Differentiation, T-Lymphocyte - immunology ; Autoantibodies - immunology ; Autoantigens - immunology ; Biological and medical sciences ; Blotting, Western ; CD2 Antigens ; CD3 Complex ; Epitopes ; Female ; Humans ; Immunomodulators ; Immunosuppression ; Kidney Transplantation - immunology ; Medical sciences ; Molecular Weight ; Muromonab-CD3 ; Pharmacology. Drug treatments ; Precipitin Tests ; Receptors, Antigen, T-Cell - immunology ; Receptors, Immunologic - analysis</subject><ispartof>Transplantation, 1990-02, Vol.49 (2), p.408-415</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-5cdcfba8e4e9f9b826f96e9af96bf691036334345de03b5458e17322647e34333</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23910,23911,25119,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5172803$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1689519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CARRENO, M</creatorcontrib><creatorcontrib>WEN-CHIC YANG</creatorcontrib><creatorcontrib>ESQUENAZI, V</creatorcontrib><creatorcontrib>FULLER, L</creatorcontrib><creatorcontrib>BURKE, G</creatorcontrib><creatorcontrib>MILGROM, M</creatorcontrib><creatorcontrib>ROTH, D</creatorcontrib><creatorcontrib>DINESH RANJAN</creatorcontrib><creatorcontrib>MILLER, J</creatorcontrib><title>OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>Four of 21 renal transplant recipients treated with OKT3 for rejection episodes developed a second sustained (approximately 2 weeks) depression in CD3 peripheral blood lymphocyte cell-surface-marker expression. This occurred after OKT3 therapy had ceased, subsequent to a return toward baseline CD3 levels seen before OKT3 therapy was instituted. The second decrease in CD3 T cell counts was dissociated from CD2 marker T cell counts using flow cytometry and coincided with transient cytomegaloviral infections. Three phases of immunosuppression were defined in these 4 patients: phase I (during OKT3 treatment); phase II (after treatment when CD3 counts were reconstituted); and phase III (when CD3 counts again were depressed). During phase III, serum of the 4 affected patients could transfer a blocking effect on the expression of the CD3 marker of peripheral blood T cells of "normal" laboratory volunteers. Contained in these sera were human IgG antibodies that bound on Western blot analysis and by radioautography after immunoprecipitation to a protein band of a T cell membrane lysate with an m.w. of 23 kD. The reaction was identical to that seen with OKT3 (immunoprecipitation). Moreover, this Western blot binding could be virtually (but not completely) eliminated by multiple absorptions of the T cell membrane lysate with OKT3. By using an affinity-purified human anti-OKT3 IgG from one of the 4 patients, it was possible to immunoabsorb from phase III sera the CD3 blocking activity as well as the binding to the 23 KD protein band. A reverse immune absorption by the phase III sera with the anti-OKT3 IgG after ultracentrifugation prevented the anti-OKT3 IgG from binding to OKT3 coated plates in solid-phase radioimmunoassay. These data support the notion that autoimmune human anti-anti-id (Ab2) antibodies can occasionally be generated by treatment with OKT3, which are directed against CD3 complex epitopes similar to the ligand of OKT3.</description><subject>Adolescent</subject><subject>Antibodies, Anti-Idiotypic - immunology</subject><subject>Antibodies, Anti-Idiotypic - isolation &amp; purification</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antigens, CD - analysis</subject><subject>Antigens, Differentiation, T-Lymphocyte - analysis</subject><subject>Antigens, Differentiation, T-Lymphocyte - immunology</subject><subject>Autoantibodies - immunology</subject><subject>Autoantigens - immunology</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>CD2 Antigens</subject><subject>CD3 Complex</subject><subject>Epitopes</subject><subject>Female</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppression</subject><subject>Kidney Transplantation - immunology</subject><subject>Medical sciences</subject><subject>Molecular Weight</subject><subject>Muromonab-CD3</subject><subject>Pharmacology. Drug treatments</subject><subject>Precipitin Tests</subject><subject>Receptors, Antigen, T-Cell - immunology</subject><subject>Receptors, Immunologic - analysis</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUdFOHSEQJU2N3qqfYMJD07dtYYEFHhtTtamJL_q8YdlZg-7Cyuza3H692Hu1jyUZyJw5c4A5hFDOvnJm9TdWljaWVdxaxuqSVSVE84FsuBKyaphhH8mGMckrLoQ-Ip8QHwpFCa0PySFvjFXcbsifm1-3gobYr34JKdLn4GjoQ1q2c_A0wvI75UekaaBTyDnlKkzuHmiYpjUmXOc5A2J4BuriEnbo_Zi6dQwRiyzNEN1Il-wizmPhFMCHOUBc8IQcDG5EON2fx-Tu4sft-VV1fXP58_z7deVlzZZK-d4PnTMgwQ62M3Uz2AasK3s3NJaXXwshhVQ9MNEpqQxwLeq6kRoKLsQx-bLTnXN6WgGXdgroYSzPgbRiq20jjVTyv0SulBaWvyqaHdHnhJhhaOdc5pK3LWftqz_tmz_tuz_tX39K69n-jrWboP_XuDOk1D_v6w69G4cyOB_wnaa4rg0T4gU5oZqH</recordid><startdate>19900201</startdate><enddate>19900201</enddate><creator>CARRENO, M</creator><creator>WEN-CHIC YANG</creator><creator>ESQUENAZI, V</creator><creator>FULLER, L</creator><creator>BURKE, G</creator><creator>MILGROM, M</creator><creator>ROTH, D</creator><creator>DINESH RANJAN</creator><creator>MILLER, J</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19900201</creationdate><title>OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients</title><author>CARRENO, M ; WEN-CHIC YANG ; ESQUENAZI, V ; FULLER, L ; BURKE, G ; MILGROM, M ; ROTH, D ; DINESH RANJAN ; MILLER, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-5cdcfba8e4e9f9b826f96e9af96bf691036334345de03b5458e17322647e34333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adolescent</topic><topic>Antibodies, Anti-Idiotypic - immunology</topic><topic>Antibodies, Anti-Idiotypic - isolation &amp; purification</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antigens, CD - analysis</topic><topic>Antigens, Differentiation, T-Lymphocyte - analysis</topic><topic>Antigens, Differentiation, T-Lymphocyte - immunology</topic><topic>Autoantibodies - immunology</topic><topic>Autoantigens - immunology</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>CD2 Antigens</topic><topic>CD3 Complex</topic><topic>Epitopes</topic><topic>Female</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppression</topic><topic>Kidney Transplantation - immunology</topic><topic>Medical sciences</topic><topic>Molecular Weight</topic><topic>Muromonab-CD3</topic><topic>Pharmacology. Drug treatments</topic><topic>Precipitin Tests</topic><topic>Receptors, Antigen, T-Cell - immunology</topic><topic>Receptors, Immunologic - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CARRENO, M</creatorcontrib><creatorcontrib>WEN-CHIC YANG</creatorcontrib><creatorcontrib>ESQUENAZI, V</creatorcontrib><creatorcontrib>FULLER, L</creatorcontrib><creatorcontrib>BURKE, G</creatorcontrib><creatorcontrib>MILGROM, M</creatorcontrib><creatorcontrib>ROTH, D</creatorcontrib><creatorcontrib>DINESH RANJAN</creatorcontrib><creatorcontrib>MILLER, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CARRENO, M</au><au>WEN-CHIC YANG</au><au>ESQUENAZI, V</au><au>FULLER, L</au><au>BURKE, G</au><au>MILGROM, M</au><au>ROTH, D</au><au>DINESH RANJAN</au><au>MILLER, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>1990-02-01</date><risdate>1990</risdate><volume>49</volume><issue>2</issue><spage>408</spage><epage>415</epage><pages>408-415</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>Four of 21 renal transplant recipients treated with OKT3 for rejection episodes developed a second sustained (approximately 2 weeks) depression in CD3 peripheral blood lymphocyte cell-surface-marker expression. This occurred after OKT3 therapy had ceased, subsequent to a return toward baseline CD3 levels seen before OKT3 therapy was instituted. The second decrease in CD3 T cell counts was dissociated from CD2 marker T cell counts using flow cytometry and coincided with transient cytomegaloviral infections. Three phases of immunosuppression were defined in these 4 patients: phase I (during OKT3 treatment); phase II (after treatment when CD3 counts were reconstituted); and phase III (when CD3 counts again were depressed). During phase III, serum of the 4 affected patients could transfer a blocking effect on the expression of the CD3 marker of peripheral blood T cells of "normal" laboratory volunteers. Contained in these sera were human IgG antibodies that bound on Western blot analysis and by radioautography after immunoprecipitation to a protein band of a T cell membrane lysate with an m.w. of 23 kD. The reaction was identical to that seen with OKT3 (immunoprecipitation). Moreover, this Western blot binding could be virtually (but not completely) eliminated by multiple absorptions of the T cell membrane lysate with OKT3. By using an affinity-purified human anti-OKT3 IgG from one of the 4 patients, it was possible to immunoabsorb from phase III sera the CD3 blocking activity as well as the binding to the 23 KD protein band. A reverse immune absorption by the phase III sera with the anti-OKT3 IgG after ultracentrifugation prevented the anti-OKT3 IgG from binding to OKT3 coated plates in solid-phase radioimmunoassay. These data support the notion that autoimmune human anti-anti-id (Ab2) antibodies can occasionally be generated by treatment with OKT3, which are directed against CD3 complex epitopes similar to the ligand of OKT3.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>1689519</pmid><doi>10.1097/00007890-199002000-00036</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0041-1337
ispartof Transplantation, 1990-02, Vol.49 (2), p.408-415
issn 0041-1337
1534-6080
language eng
recordid cdi_proquest_miscellaneous_79648454
source MEDLINE; Journals@Ovid Complete
subjects Adolescent
Antibodies, Anti-Idiotypic - immunology
Antibodies, Anti-Idiotypic - isolation & purification
Antibodies, Monoclonal - immunology
Antigens, CD - analysis
Antigens, Differentiation, T-Lymphocyte - analysis
Antigens, Differentiation, T-Lymphocyte - immunology
Autoantibodies - immunology
Autoantigens - immunology
Biological and medical sciences
Blotting, Western
CD2 Antigens
CD3 Complex
Epitopes
Female
Humans
Immunomodulators
Immunosuppression
Kidney Transplantation - immunology
Medical sciences
Molecular Weight
Muromonab-CD3
Pharmacology. Drug treatments
Precipitin Tests
Receptors, Antigen, T-Cell - immunology
Receptors, Immunologic - analysis
title OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A28%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=OKT3%20induction%20via%20idiotypic%20networks%20of%20mirror-image%20immunosuppressive%20antiimmunoglobulins%20in%20renal%20transplant%20recipients&rft.jtitle=Transplantation&rft.au=CARRENO,%20M&rft.date=1990-02-01&rft.volume=49&rft.issue=2&rft.spage=408&rft.epage=415&rft.pages=408-415&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-199002000-00036&rft_dat=%3Cproquest_cross%3E15573913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15573913&rft_id=info:pmid/1689519&rfr_iscdi=true